Non-steroidal anti-inflammatory drugs with selective inhibitory activity on cyclooxygenase 2. Interest and future prospects;Les anti-inflammatoires non steroidiens inhibiteurs selectifs de la cyclooxygenase 2. Interet et perspectives

Revue de Medecine Interne

Volumn 21, Issue 11, 2000, Pages 978-988

  Blain, H ^a,b   Jouzeau, J Y ^b   Netter, P ^b   Jeandel, C ^a  

^a CHU   (France)

^b CNRS   (France)

Author keywords

Alzheimer's disease; Colorectal cancer; COX 2 inhibitor; Cyclooxygenase; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CANCER RISK; COLORECTAL CANCER; DRUG MECHANISM; DUODENUM ULCER; HUMAN; INFLAMMATION; OSTEOARTHRITIS; PROSTAGLANDIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; STOMACH HEMORRHAGE; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; COMPARATIVE STUDY; GASTROINTESTINAL HEMORRHAGE; METABOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0033763924     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(00)00254-X     Document Type: Review

References (82)

1. Epidemiology of NSAID-related gastrointestinal side effects
2. Cyclooxygenase in biology and disease
3. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase)
4. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence
5. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1
6. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes
7. Human cyclooxygenase-2 cDNA
8. The classification of cyclooxygenase inhibitors
9. Diclofenac/misoprostol: Novel findings and their clinical potential
10. Safety of meloxicam: A global analysis of clinical trials
11. Risk of hospitalization for upper gastrointestinal bleeding associated with ketorolac, other NSAIDs, calcium antagonist and other antihypertensive drags
12. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers
13. Preliminary study of the safety and efficacy of SC58635, a novel cyclooxygenase 2 inhibitor
14. New pharmacological strategies for pain relief
15. Analysis of the effects of cyclooxygenase (COX)-I and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor
16. N-methyl D-aspartate induced mechanical allodynia is blocked by nitric oxide synthase and COX-2 inhibitors
17. Analgesic activity of the novel COX2 preferring NSAID, meloxicam, in mono-arthritic rats: Central and peripheral components
18. Expression of cyclooxygenase-2 in human and in animal model of rheumatologic arthritis
19. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage: Influence of nitric oxide
20. Outcome of specific COX-2 inhibition in rheumatoid arthritis
21. Pain management in osteoarthritis: The role of COX-2 inhibitors
22. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occuring fever in humans
23. Arachidonic acid metabolism and pathophysiologic aspects of subarachnoid hemorrhage in rats
24. Effect of a novel thromboxan A2 receptor antagonist, S-1452, on postischemic brain injury in rats
25. Attenuation of postischemic brain hypoperfusion and reperfusion injury by the cyclooxygenase-lipoxygenase inhibitor BW755C
26. Brain eicosanoid levels during temporary focal cerebral ischemia in rats: A microdialysis study
27. Effect of indomethacin and free radical scavenger on cerebral blood flow and edema after cerebral artery occlusion in cats
28. Effect of ibuprofen on regional eicosanoid production and neuronal injury after forebrain ischemia in rats
29. Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia
30. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
31. NSAIDs and cognition in Alzheimer's disease
32. Risk of Alzheimer's disease and duration of NSAID use
33. Clinical trial of indomethacin in Alzheimer's disease
34. Maladie d'Alzheimer et anti-inflammatoires non steroidiens selectifs de COX-2. Justification et perspectives
35. Analgesics and NSAID in the treatment of the acute migraine attack
36. Eicosanoids and nitric oxide influence induction of reactive gliosis from spreading depression in microglia but not astrocytess
37. Nitric oxide and prostaglandins interact to mediate arteriolar dilatation during cortical spreading depression
38. The effect of cyclooxygenase-2 inhibitor on experimental allergic neuritis
39. Immunoregulatory molecules and I1-2 receptors identified in multiple sclerosis brain
40. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease
41. Aids-related dementia and calcium homeostasis
42. Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia
43. Enzymatic oxidation of dopamine: The role of prostaglandin H-synthase
44. Prostaglandin H synthetase-mediated metabolism of dopamine: Implication of Parkinson's disease
45. NSAID use and decreased risk of gastrointestinal cancers
46. Colorectal cancer and non steroidal anti-inflammatory drugs
47. The role of nonsteroidal antiinflammatory drugs in colorectal cancer prevention
48. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azomethane induced colonic tumours in rats
49. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect
50. Suppression of intestinal polyposis in Apc716 knochout mice by inhibition of cyclooxygenase 2 (COX-2)
51. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administred during different stages of carcinogenesis
52. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
53. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2
54. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
55. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
56. Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway
57. Sulfone metabolite of sulindac inhibits mamary carcinogenesis
58. Sulindac sulfone inhibits azomethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
59. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: Enhanced apoptosis in carcinoma cell lines
60. Apoptosis and APC in colorectal tumorigenesis
61. Aspirin and aspirin-like drugs induce the expression of HLA-DR in HT29 colon adenocarcinoma cells
62. Sulindac for polyposis of the colon
63. Aspirin and the risk of colorectal cancer in women
64. Rectal cancer in FAP patients after sufindac
65. Cyclooxygenase-2 expression in human oesophageal carcinoma
66. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice
67. Expression of cyclooxygenase-2 in human lung carcinoma
68. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas
69. Cyclooxygenase-2 expression in hepatocellular carcinoma
70. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma
71. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey
72. Mol Carcinog
73. Induction of cyclooxygenase-2 in brain during acute and chronic ethanol treatment and ethanol withdrawal
74. Ovarian cell differenciation: A cascade of multiple hormones, cellular signals, and regulated genes
75. Differential effects of nonsteroidal antiinflammatory drugs on constitutive and inducible prostaglandin G/H synthase in cultures bone cell
76. Developmental expression of the cyclooxygenase-1 and cyclooxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids
77. Expression of a mitogen-inducible cyclooxygenase in brain neuron: Regulation by synaptic activity and glucocorticoids
78. Expression of cyclooxygenase 2 in rat brain following kainate treatment
79. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
80. Prostaglandin synthase 2 disruption causes severe renal pathology in the mouse
81. Renal abnormalities and an alterated inflammatory response in mice lacking cyclooxygenase 2
82. Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 nuff cells